STOCK TITAN

Xenetic Biosciences Inc - XBIO STOCK NEWS

Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.

Xenetic Biosciences Inc (NASDAQ: XBIO) is a clinical-stage biopharmaceutical leader advancing novel immuno-oncology therapies through its DNase platform and polyxen™ technology. This page provides investors and researchers with centralized access to the company’s latest developments in cancer treatment innovation.

Find timely updates on XBIO’s clinical trial progress, strategic collaborations, and regulatory milestones. Our curated collection includes press releases about orphan-designated therapies, CAR T platform advancements, and preclinical research insights – all essential for tracking the company’s contributions to targeted cancer treatments.

Key updates cover three focus areas: clinical developments in hard-to-treat cancers, technology partnerships enhancing therapeutic efficacy, and scientific publications validating novel approaches to tumor microenvironment modulation. Bookmark this page to stay informed about Xenetic’s progress in developing next-generation biologics and combination therapies.

Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) reported its second quarter 2022 results, highlighting a significant in-licensing deal that expands its oncology pipeline with a focus on DNase-based therapies. The company aims to advance its DNase program towards a Phase 1 study targeting pancreatic carcinoma and other advanced solid tumors. Financially, Xenetic ended the quarter with $14.9 million in cash but posted a net loss of approximately $2.7 million. R&D expenses surged by 296.1% due to investments in the new DNase platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.77%
Tags
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) and VolitionRx Limited (NYSE AMERICAN: VNRX) announced a collaboration to develop Neutrophil Extracellular Traps (NETs) targeted, adoptive cell therapies for cancer treatment. The program aims to evaluate the integration of Volition's Nu.Q® NETs Test with Xenetic's DNase-Armored CAR T platform to potentially address multiple solid tumor types. Volition will fund the research, sharing proceeds from commercialization. The collaboration highlights both companies' commitment to innovative cancer therapies and reflects Xenetic's recent acquisition of the DNase platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
none
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) has entered into a manufacturing agreement with Catalent Pharma Solutions to advance its DNase-based oncology platform aimed at enhancing treatment outcomes for solid tumors, including pancreatic carcinoma. The agreement facilitates cGMP manufacturing for Human DNase I, supporting the company's planned first-in-human study combining DNase with immune checkpoint inhibitors or chemotherapy. This collaboration signifies a strategic step towards developing innovative therapies for difficult-to-treat cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.58%
Tags
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) will host a Virtual Investor Innovation in Oncology Event on June 9, 2022, at 11:00 AM ET. The event features a moderated roundtable with the company's leadership and surgical oncology expert, Allan Tsung, MD. The discussion will cover their innovative DNase oncology platform targeting solid tumors and the personalized CAR T platform for B-Cell lymphomas. Investors can submit questions during the event. A live webcast will be available, and a replay will be accessible for 90 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
conferences
-
Rhea-AI Summary

Xenetic Biosciences, Inc. (NASDAQ: XBIO) will participate in a Virtual Investor Innovation in Oncology Event on June 9, 2022, at 11:00 AM ET. The event features a roundtable with CEO Jeffrey Eisenberg, Chief Scientific Officer Curtis Lockshin, and oncology expert Allan Tsung, MD. They will discuss Xenetic's DNase-based oncology platform, focusing on how it targets Neutrophil Extracellular Traps (NETs) in cancer treatment. A live video webcast will be available on the Company's website, and questions from the audience will be addressed during the session.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
conferences
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO), a biopharmaceutical company focused on immune-oncology technologies, will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 4:00 PM ET. CEO Jeffrey F. Eisenberg will deliver the presentation in Miami, FL, and virtually. The management team will also be available for one-on-one meetings with investors. A live video webcast will be accessible on the Company's website and archived for 90 days. Xenetic is advancing therapies targeting Neutrophil Extracellular Traps and developing CAR T platform technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
conferences
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) reported its first quarter 2022 financial results, highlighting a net loss of approximately $1.6 million and cash reserves of $16.2 million. The company has completed an exclusive licensing agreement with CLS Therapeutics for a DNase-based oncology platform aimed at enhancing cancer treatment outcomes. The focus is on advancing this platform for Phase 1 clinical development targeting locally advanced or metastatic solid tumors, with an IND filing anticipated by the end of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) has announced a transaction with CLS Therapeutics to develop a DNase-based oncology platform, which aims to enhance the efficacy of existing therapies for solid tumors. This includes an exclusive license for DNases in cancer treatment, entailing an upfront payment of $500,000, issuance of shares, and future milestone payments potentially reaching $13 million. The company plans to conduct a Phase 1 clinical study targeting locally advanced or metastatic cancers. The platform seeks to address issues related to Neutrophil Extracellular Traps (NETs), which may hinder cancer treatment outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.83%
Tags
none
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) reported a net loss of $5.6 million for the year ended December 31, 2021, with research and development expenses rising to $3.2 million. The company ended the year with cash reserves of approximately $18.2 million and working capital of about $17.3 million, up from $11.4 million in 2020. Their XCART platform is advancing toward IND-enabling studies, while royalty payments from the PolyXen technology reached $1.2 million, a 166% increase from the previous year. The XCART program targets a potential global market of over $7 billion annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) is advancing its XCART platform towards IND-enabling studies, backed by a strengthened cash position from a recent $12.5 million private placement. The company reported a net loss of $1.4 million for Q3 2021, with R&D expenses rising by 36.1% to $0.8 million. Additionally, royalty streams have grown through its license agreement with PolyXen®, bringing in approximately $0.3 million in royalties. With working capital at $19.5 million, Xenetic is positioned to pursue its innovative cancer therapies effectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
Xenetic Biosciences Inc

Nasdaq:XBIO

XBIO Rankings

XBIO Stock Data

3.76M
1.25M
19.06%
6.44%
0.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
FRAMINGHAM